GlassScriptPhysician profile
Gary P Cardiello
NPI 1114020690
$7,972.32
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,724 · 2020: $1,501 · 2021: $1,584 · 2022: $1,269 · 2023: $1,232 · 2024: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $880.99 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $820.96 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Astrazeneca Pharmaceuticals LP | $660.85 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $646.51 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $615.25 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $493.01 | 2021-2023 | Synthroid, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.99 | 2019-2024 | Jardiance |
| Sunovion Pharmaceuticals INC. | $304.93 | 2019-2022 | |
| Allergan, INC. | $288.71 | 2019-2020 | |
| Amgen INC. | $257.08 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $237.58 | 2019-2023 | |
| Amarin Pharma, INC. | $193.26 | 2019-2022 | |
| Pfizer INC. | $184.38 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $167.14 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $155.90 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cardiello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.